Progenity Shares Two Poster Presentations on Treatment of Gastrointestinal Disorders at ECCO’22
Patient data establishes key correlations for therapeutic exposure in tissue and alternative inflammatory pathways, supporting…
Year: 2022
Sorrento Announces COVISHIELD (STI-9167) Antibody Strongly Neutralizes BA.2 Omicron Sublineage Virus as Well as BA.1 and BA.1+R346k Omicron Viruses
STI-9167 neutralizing antibody (nAb) maintains high neutralization potency against the recently emerging Omicron sublineage BA.2…
Quotient Limited to Participate in the Cowen 42nd Annual Health Care Conference
JERSEY, Channel Islands, Feb. 22, 2022 (GLOBE NEWSWIRE) — Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics…
Praxis Precision Medicines to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage…
QuantuMDx announces approval of its Rapid Q-POC™ SARS-CoV-2 assay in the UK under CTDA legislation
QuantuMDx announces approval of its Rapid Q-POCTMSARS-CoV-2 assay in the UK under CTDA legislation NEWCASTLE…
Acer Therapeutics Announces Appointment of Adrian Quartel, M.D., FFPM, as Chief Medical Officer
Industry veteran with over 20 years of drug development experience to oversee advancement of Acer’s…
Nuvectis Announces Positive Data for NXP900 in Triple Negative Breast Cancer Preclinical Models with an Integrin-Linked Kinase (ILK) Loss
Data Published in Cancer Research, a journal of the American Association for Cancer Research Publication…
Albireo to Report Q4 and Year-End 2021 Financial Results on March 1
— Conference call and webcast to be held at 10:00 a.m. ET — BOSTON, Feb….
Chinook Therapeutics Announces Upcoming Presentations at 4th Annual Chronic Kidney Disease Drug Development Summit
SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) — Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company…
Akoya to Report Fourth Quarter and Full Year 2021 Financial Results on March 14th, 2022 and Present at the Cowen Annual Health Care Conference on March 8th, 2022
MARLBOROUGH, Mass., Feb. 22, 2022 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The…
Black Diamond Therapeutics Appoints Elizabeth Montgomery as Chief People Officer
CAMBRIDGE, Mass. and NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc….
Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 1, 2022
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical…
Athenex Announces Appointment of Chief Financial Officer
BUFFALO, N.Y., Feb. 22, 2022 (GLOBE NEWSWIRE) — Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical…
Aquestive Therapeutics to Report Fourth Quarter and Year End 2021 Financial Results and Recent Business Highlights on March 8 and Host Conference Call on March 9 at 8:00 a.m. ET
WARREN, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022
SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company…
PROCEPT BioRobotics Corp. to Report Fourth Quarter and Full Year 2021 Financial Results on March 8, 2022
REDWOOD CITY, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — PROCEPT® BioRobotics Corporation (Nasdaq: PRCT), a…
Morphic Presents Positive MORF-057 Data in Oral Presentation at ECCO 2022
New preclinical data expand understanding of α4β7-expressing immune cells and MORF-057 dose response Data support…
Supernus Receives Notice Assigning Early October 2022 PDUFA for SPN-830 Apomorphine Infusion Device NDA
ROCKVILLE, Md., Feb. 22, 2022 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical…
ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease
ImmixBio Initiates GMP Manufacturing of IMX-120, a Biologic for Inflammatory Bowel Disease Immix Biopharma, Inc….
CytomX Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 (GLOBE NEWSWIRE) — CytomX Therapeutics, Inc. (Nasdaq: CTMX),…